Skip to main content

Table 3 Univariate analysis of patients’ PFS of CAR T cells immunotherapy and possible prognostic factors

From: The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

prognostic factor case(n) Median PFS (months) Mean PFS (months, 95%CL) 1-year PFS (%, 95%CL) p-value
Ag recognition moieties
 CD19 81 10 24.11*(18.35–29.87) 46.12%(34.20–57.22%  
 CD20 9 12 11.5(6.61–16.39) 33.33%(7.83–62.26%) 0.3309
Disease
 leukemia 42 7 20.30*(12.56–28.04) 40.19%(24.41–55.47%)  
 lymphoma 48 12 18.10*(13.37–22.82) 48.22%(32.68–62.14%) 0.3123
T cell origin
 Autologous 74 12 22.33*(16.62–28.04) 45.60%(33.47–56.92%)  
 Allogeneic 16 3 8.41*(5.23–11.59) 47.73%(22.05–69.64%) 0.1779
Generation
 1st 11 10.4 18.52*(9.86–27.18) 45.45%(16.66–70.69%)  
 2nd 76 10 22.69*(16.40–28.98) 45.41%(33.11–56.91%) 0.7754
costimulatory domains
 CD137 and CD3ζ 28 6 16.44*(8.41–24.46) 33.39%(16.56–51.22%)  
 CD28 and CD3ζ 46 14.50*(11.63–17.37) 56.29%(39.42–70.14%) 0.0489
T cell activation
 OKT3 43 12 12.76(9.80–15.73) 40.32%(23.45–56.63%)  
 CD3/CD28 beads 34 12.6 25.02*(16.78–33.26) 52.78%(34.90–67.84%) 0.3961
IL-2 to cells
 yes 57 12.6 18.91*(14.15–23.67) 50.10%(35.63–62.95%)  
 no 28 12 18.60*(10.86–26.34) 38.27%(19.56–56.81%) 0.616
transfection methods
 non-viral vector 6 12 12.83(7.72–1.94) 33.33%(4.61–67.56%)  
 viral vector 94 10 23.99*(18.34–29.64) 45.75%(34.12–56.63%) 0.4634
Lymphodepletion
 yes 53 10 18.58*(12.16–24.99) 39.07%(25.16–52.72%)  
 no 21 5 8.18*(5.49–10.87) 37.25%(12.81–62.22%) 0.3282
CART cells
 ≥ 108 54 8 21.43*(14.34–28.51) 42.01%(28.04–55.35%)  
 < 108 23 30.15*(20.10–40.20) 58.38%(34.69–76.06%) 0.1471
IL-2 administration to patients
 yes 13 12 13.44(9.19–17.70) 29.92%(7.49–57.01%)  
 no 77 10 23.05*(16.19–27.05) 47.06%(34.99–58.22%) 0.9355
T cell persistence time
 ≥ 2 months 44 10 18.33*(11.34–25.32) 37.26%(21.95–52.59%)  
 < 2 months 46 12.6 18.82*(13.56–24.09) 50.62%(34.60–64.60%) 0.2986
Peak serum IL-2 level
 ≥ 50 pg/mL 8 12 12*(7.84–16.16) 41.67%(7.20–74.73%)  
 < 50 pg/mL 8 9 7.78*(3.61–11.94) 26.25%(1.27–66.37%) 0.4159
  1. (*) largest observed analysis time is censored, mean is underestimated